Global Multiple Sclerosis Treatment Market is Growing with 4.5% CAGR in the Forecast Period of 2020 to 2027

Global Multiple Sclerosis Treatment Market is growing with the factors such as increasing prevalence of multiple sclerosis and rising government initiatives. Increasing need for better multiple sclerosis treatment options also acts as a major factor for the growth of the market. Extensive research and development activity in multiple sclerosis treatment has also given a boom to the global multiple sclerosis treatment market.

Increasing awareness for multiple sclerosis treatment has propelled the demand of the market. However, patent expiry of drugs and high cost of treatment have decreased the demand of the market.

Global Multiple Sclerosis Treatment Market Scenario             

According to Data Bridge Market Research, the market for global multiple sclerosis treatment in North America has the highest market share followed by Europe and Asia-Pacific. Market leader is Novartis AG, which accounts an estimated market share of approximately 14.53% in the global market. The company has gained outstanding sale by providing advanced multiple sclerosis treatment.

For instance,

  • in January 2020, Novartis AG received EU approval for Mayzent (siponimod) which is the first and only treatment used for multiple sclerosis treatment. This approval enhanced the company’s product portfolio for MS treatment and allowed it generate more revenue.

Multiple Sclerosis Treatment MarketTrends Impacting the Market

Now the question is which are the other regions that Novartis AG, Genzyme Corporation (A Business Unit of Sanofi), Merck KGaA are targeting? Data Bridge Market Research has forecasted a large growth in North America multiple sclerosis treatment market and the market leaders are targeting the U.S. and Canada to be their next pocket revenue for 2020.

The multiple sclerosis treatment market is becoming more competitive with companies such as Novartis AG, Genzyme Corporation (A Business Unit of Sanofi), Merck KGaA. These are the top dominating companies in multiple sclerosis treatment market and are launching more new drugs in the market. The data bridge market research new reports highlight the major growth factors and opportunities in the global multiple sclerosis treatment market.

For more analysis on the multiple sclerosis treatment market, request for a briefing with our analysts. https://www.databridgemarketresearch.com/speak-to-analyst/?dbmr=global-multiple-sclerosis-treatment-market

New Market Developments

  • In April 2020, Genzyme Corporation obtained positive data from the phase 2b clinical trial of BTK inhibitor (SAR442168) when administered in multiple sclerosis patients. This product has been reported to reduce the neuroinflammation and neurodegeneration caused by multiple sclerosis.
  • In March 2019, Merck KGaA received FDA approval for MAVENCLAD, used for treatment of relapsing-remitting MS and active secondary progressive multiple sclerosis. This approval helped the company to enhance its product portfolio for MS treatment and to earn more revenue.

Scope of the Global Multiple Sclerosis Treatment Market

Global multiple sclerosis treatment market is segmented on the basis of countries into the U.S., Canada and Mexico, U.K., Germany, France, Spain, Italy, Netherlands, Switzerland, Russia, Belgium, Turkey, Austria, Norway, Hungary, Lithuania, Ireland, Poland and rest of Europe, China, South Korea, Japan, India, Australia, Singapore, Malaysia, Indonesia, Thailand, Philippines Vietnam and rest of Asia-Pacific, South Africa, Saudi Arabia, U.A.E., Israel, Kuwait, Egypt and rest of Middle East and Africa, Brazil, Argentina, Peru and rest of South America.

  • All country based analysis of the global multiple sclerosis treatment market is further analysed based on maximum granularity into further segmentation. On the basis of disease type, the global multiple sclerosis treatment market is segmented into relapsing–remitting multiple sclerosis (RRMS), secondary progressive multiple sclerosis (SPMS), primary progressive multiple sclerosis (PPMS) and severe relapsing–remitting multiple sclerosis (RES). On the basis of treatment, the global multiple sclerosis treatment market is segmented into symptomatic therapies, abortive therapies/treatment of acute exacerbations and preventive therapies. On the basis of drug type, the multiple sclerosis treatment market is segmented into branded and generic. On the basis of route of administration, the multiple sclerosis treatment market is segmented into oral and parenteral. On the basis of end user, the multiple sclerosis treatment market is segmented into hospital, specialty centers, homecare and others. On the basis of distribution channel, the multiple sclerosis treatment market is segmented into direct tender and retail sales.

To know more about the study https://www.databridgemarketresearch.com/reports/global-multiple-sclerosis-treatment-market

Key Pointers Covered In Global Multiple Sclerosis Treatment Market Industry Trends and Forecast to 2027

  • Market Size
  • Top to Bottom Market Analysis
  • Recent Developments for Market Competitors
  • Recent Market Value for Different Countries
  • Market value and over view of multiple sclerosis treatment market
  • Company profiling of top eight players of multiple sclerosis treatment market

Key Market Competitors Covered in the Global Multiple Sclerosis Treatment Market Report

  • Genzyme Corporation (A Subsidiary of Sanofi)
  • Teva Pharmaceuticals USA, Inc. (A Subsidiary of Teva Pharmaceuticals Industries Ltd.)
  • F. Hoffmann-La Roche Ltd, Merck KGaA
  • Mallinckrodt
  • Pfizer Inc.
  • Hikma Pharmaceuticals PLC
  • Par Pharmaceutical (A Subsidiary of Endo International plc),
  • Mylan N.V.
  • Acorda Therapeutics, Inc.
  • Novartis AG
  • Biogen
  • CELGENE CORPORATION (A Subsidiary of Bristol-Myers Squibb Company)
  • Lannett
  • Zydus Pharmaceuticals, Inc. (A Subsidiary of Zydus Cadila)
  • Bayer AG
  • Amneal Pharmaceuticals LLC
  • Adamas Pharmaceuticals, Inc.

Above are the key players covered in the report, to know about more and exhaustive list of multiple sclerosis treatment companies’, contact us https://www.databridgemarketresearch.com/toc/?dbmr=global-multiple-sclerosis-treatment-market

Research Methodology: Global Multiple Sclerosis Treatment Market

Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analyzed and forecasted using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please request an analyst call or can drop down your enquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include vendor positioning grid, market time line analysis, market overview and guide, company positioning grid, company market share analysis, standards of measurement, top to bottom analysis and vendor share analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Primary Respondents

  • Demand Side: Manufacturer, Healthcare Industry, Neurologists, Scientists, Research Laboratories
  • Supply Side: Product Managers, Marketing Managers, C-Level Executives, Distributors, Market Intelligence, and Regulatory Affairs Managers among others.

Related Reports

Browse in Healthcare Category Related Reports@ https://www.databridgemarketresearch.com/report-category/healthcare/